Etid klinik pou BPCO nan Nevada
8 etid pou BPCO ap chèche patisipan nan sit nan Nevada.
Vil nan Nevada
Tèks ofisyèl etid la (Anglè)
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Henderson Clinical Trials- Site Number : 8400026, Henderson
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07190209Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Excel Clinical Research - Las Vegas- Site Number : 8400070, Las Vegas
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07190222A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Las Vegas
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06883305A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Henderson Clinical Trials, Henderson
Ap rekriteFaz 2/3
Laj 35 a 80 · Tout sèks · Mizajou Aug 31, 2026 · NCT07363694A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Las Vegas
- Research Site, Las Vegas
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Aug 26, 2026 · NCT06283966eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Henderson
- GSK Investigational Site, Las Vegas
- GSK Investigational Site, Reno
Ap rekriteFaz 3
Laj 40 a 75 · Tout sèks · Mizajou Jul 28, 2026 · NCT07177339Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Las Vegas
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Apr 9, 2026 · NCT06961214Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Renown Regional Medical Center, Reno
Ap rekriteEtid obsèvasyon
Laj 50 ak plis · Tout sèks · Mizajou Aug 5, 2025 · NCT06122077Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.